Gentamicin Inj Rx
Generic Name and Formulations:
Gentamicin sulfate 40mg/mL; IM, or IV inj after dilution; contains sulfites.
Various generic manufacturers
Indications for Gentamicin Inj:
Serious susceptible infections.
Obesity: Base dose on lean body mass. Usual duration 7–10 days. 1mg/kg IM or IV every 8 hours; max 5mg/kg/day. For alternative dosing regimens (eg, extended intervals) see literature.
Premature and infants <1 week: 2.5mg/kg every 12 hours. Neonates: 2.5mg/kg every 8 hours. Others: 2–2.5mg/kg every 8 hours.
Monitor for nephro- and neurotoxicity; avoid peak serum levels >12micrograms/mL (when dosed at conventional intervals) and trough levels >2micrograms/mL. Renal impairment: reduce dose, see literature; maintain adequate hydration. Prolonged use or excessive doses. Asthma. Neuromuscular disorders. Elderly. Pregnancy (Cat.D): not recommended.
Avoid concomitant furosemide, ethacrynic acid, other nephro/neurotoxic drugs including cephalosporins. May potentiate neuromuscular blockade.
Nephro- or neurotoxicity, respiratory depression, lethargy, confusion, depression, visual disturbances, elevated liver enzymes, blood dyscrasias.
Formerly known under the brand names Garamycin, Gentafair.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline